{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"ORR (partial remission or better) to induction therapy following 4 cycles of the combination regimen BBd.","groups":[{"description":"Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2; bortezomib SC on days 1, 8, 15, and 22; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 35 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving less than a VGPR or with more than 10% bone marrow plasmacytosis may receive 2 additional courses.\n\nBendamustine hydrochloride: Given IV\n\nBortezomib: Given SC\n\nDexamethasone: Given PO","id":"OG000","title":"Bendamustine, Bortezomib, Dexamethasone (Standard)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"4 subjects were not evaluable - (1 didn't get any therapy on study, 1 received only first cycle and 2 developed medical issues that took them off study during the first cycle)","reportingStatus":"POSTED","timeFrame":"At least 140 days","title":"Count of Participants That Experience Overall Response Following 4 Cycles of the Combination Regimen BBd","type":"PRIMARY","unitOfMeasure":"Participants"}